Chintu Patel - Mar 3, 2022 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
Co-CEO, Director
Signature
/s/ Meredith Cook, as Attorney-in-Fact
Stock symbol
AMRX
Transactions as of
Mar 3, 2022
Transactions value $
$0
Form type
4
Date filed
3/3/2022, 08:19 PM
Previous filing
Dec 17, 2021
Next filing
Mar 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Performance-Based Restricted Stock Units Award $0 +1.16M $0.00 1.16M Mar 3, 2022 Class A Common Stock 1.16M Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 Represents a performance-based restricted stock unit grant of 579,710 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period.